The present invention relates to stable pharmaceutical compositions comprisingone or more HMG-CoA reductase inhibitors, processes for preparing the stablecompositions and uses for the compositions. The stable pharmaceutical compositionsof the invention may be used, in particular, for the treatment of hyperlipoproteinemiaand atherosclerosis.